Literature DB >> 28566218

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

Stephen Zewinger1, Marcus E Kleber2, Vinicius Tragante3, Raymond O McCubrey4, Amand F Schmidt5, Kenan Direk5, Ulrich Laufs6, Christian Werner6, Wolfgang Koenig7, Dietrich Rothenbacher8, Ute Mons9, Lutz P Breitling9, Herrmann Brenner10, Richard T Jennings1, Ioannis Petrakis1, Sarah Triem1, Mira Klug1, Alexandra Filips1, Stefan Blankenberg11, Christoph Waldeyer11, Christoph Sinning11, Renate B Schnabel11, Karl J Lackner12, Efthymia Vlachopoulou13, Ottar Nygård14, Gard Frodahl Tveitevåg Svingen15, Eva Ringdal Pedersen16, Grethe S Tell17, Juha Sinisalo18, Markku S Nieminen18, Reijo Laaksonen19, Stella Trompet20, Roelof A J Smit20, Naveed Sattar21, J Wouter Jukema22, Heinrich V Groesdonk23, Graciela Delgado24, Tatjana Stojakovic25, Anna P Pilbrow26, Vicky A Cameron26, A Mark Richards27, Robert N Doughty28, Yan Gong29, Rhonda Cooper-DeHoff29, Julie Johnson29, Markus Scholz30, Frank Beutner31, Joachim Thiery32, J Gustav Smith33, Ragnar O Vilmundarson34, Ruth McPherson34, Alexandre F R Stewart34, Sharon Cresci35, Petra A Lenzini36, John A Spertus37, Oliviero Olivieri38, Domenico Girelli38, Nicola I Martinelli38, Andreas Leiherer39, Christoph H Saely39, Heinz Drexel40, Axel Mündlein41, Peter S Braund42, Christopher P Nelson42, Nilesh J Samani42, Daniel Kofink3, Imo E Hoefer43, Gerard Pasterkamp43, Arshed A Quyyumi44, Yi-An Ko44, Jaana A Hartiala45, Hooman Allayee45, W H Wilson Tang46, Stanley L Hazen46, Niclas Eriksson47, Claes Held47, Emil Hagström47, Lars Wallentin47, Axel Åkerblom47, Agneta Siegbahn48, Igor Karp49, Christopher Labos50, Louise Pilote51, James C Engert50, James M Brophy50, George Thanassoulis50, Peter Bogaty52, Wojciech Szczeklik53, Marcin Kaczor53, Marek Sanak53, Salim S Virani54, Christie M Ballantyne55, Vei-Vei Lee56, Eric Boerwinkle57, Michael V Holmes58, Benjamin D Horne4, Aroon Hingorani5, Folkert W Asselbergs59, Riyaz S Patel5, Bernhard K Krämer24, Hubert Scharnagl25, Danilo Fliser1, Winfried März60, Thimoteus Speer1.   

Abstract

BACKGROUND: Lipoprotein(a) concentrations in plasma are associated with cardiovascular risk in the general population. Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in patients with established coronary heart disease remains less clear.
METHODS: We obtained data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. We tested associations of tertiles of lipoprotein(a) concentration in plasma and two LPA single-nucleotide polymorphisms ([SNPs] rs10455872 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox regression analysis and with severity of disease by generalised linear modelling, with and without adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. Results for plasma lipoprotein(a) concentrations were validated in five independent studies involving 10 195 patients with established coronary heart disease. Results for genetic associations were replicated through large-scale collaborative analysis in the GENIUS-CHD consortium, comprising 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies or cohorts.
FINDINGS: The median follow-up was 9·9 years. Increased severity of coronary heart disease was associated with lipoprotein(a) concentrations in plasma in the highest tertile (adjusted hazard radio [HR] 1·44, 95% CI 1·14-1·83) and the presence of either LPA SNP (1·88, 1·40-2·53). No associations were found in LURIC with all-cause mortality (highest tertile of lipoprotein(a) concentration in plasma 0·95, 0·81-1·11 and either LPA SNP 1·10, 0·92-1·31) or cardiovascular mortality (0·99, 0·81-1·2 and 1·13, 0·90-1·40, respectively) or in the validation studies.
INTERPRETATION: In patients with prevalent coronary heart disease, lipoprotein(a) concentrations and genetic variants showed no associations with mortality. We conclude that these variables are not useful risk factors to measure to predict progression to death after coronary heart disease is established. FUNDING: Seventh Framework Programme for Research and Technical Development (AtheroRemo and RiskyCAD), INTERREG IV Oberrhein Programme, Deutsche Nierenstiftung, Else-Kroener Fresenius Foundation, Deutsche Stiftung für Herzforschung, Deutsche Forschungsgemeinschaft, Saarland University, German Federal Ministry of Education and Research, Willy Robert Pitzer Foundation, and Waldburg-Zeil Clinics Isny.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28566218      PMCID: PMC5651679          DOI: 10.1016/S2213-8587(17)30096-7

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  32 in total

1.  The mysterious lipoprotein(a) is still good for a surprise.

Authors:  Claudia Lamina; Florian Kronenberg
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-27       Impact factor: 32.069

2.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano
Journal:  Atherosclerosis       Date:  2016-09-01       Impact factor: 5.162

Review 3.  Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.

Authors:  B R Winkelmann; W März; B O Boehm; R Zotz; J Hager; P Hellstern; J Senges
Journal:  Pharmacogenomics       Date:  2001-02       Impact factor: 2.533

4.  Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.

Authors:  Anselm K Gitt; Dominik Lautsch; Jean Ferrieres; John Kastelein; Heinz Drexel; Martin Horack; Philippe Brudi; Brecht Vanneste; Peter Bramlage; Francois Chazelle; Vasilisa Sazonov; Baishali Ambegaonkar
Journal:  Atherosclerosis       Date:  2016-09-09       Impact factor: 5.162

5.  Intracellular processing of apo(a) in primary baboon hepatocytes.

Authors:  A L White; D L Rainwater; J E Hixson; L E Estlack; R E Lanford
Journal:  Chem Phys Lipids       Date:  1994-01       Impact factor: 3.329

6.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

7.  Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Authors:  Michelle L O'Donoghue; David A Morrow; Sotirios Tsimikas; Sarah Sloan; Angela F Ren; Elaine B Hoffman; Nihar R Desai; Scott D Solomon; Michael Domanski; Kiyohito Arai; Stephanie E Chiuve; Christopher P Cannon; Frank M Sacks; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

8.  Common sequence variants associated with coronary artery disease correlate with the extent of coronary atherosclerosis.

Authors:  Eythor Bjornsson; Daniel F Gudbjartsson; Anna Helgadottir; Thorarinn Gudnason; Tomas Gudbjartsson; Kristjan Eyjolfsson; Riyaz S Patel; Nima Ghasemzadeh; Gudmar Thorleifsson; Arshed A Quyyumi; Unnur Thorsteinsdottir; Gudmundur Thorgeirsson; Kari Stefansson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-16       Impact factor: 8.311

9.  Lipid-related markers and cardiovascular disease prediction.

Authors:  Emanuele Di Angelantonio; Pei Gao; Lisa Pennells; Stephen Kaptoge; Muriel Caslake; Alexander Thompson; Adam S Butterworth; Nadeem Sarwar; David Wormser; Danish Saleheen; Christie M Ballantyne; Bruce M Psaty; Johan Sundström; Paul M Ridker; Dorothea Nagel; Richard F Gillum; Ian Ford; Pierre Ducimetiere; Stefan Kiechl; Wolfgang Koenig; Robin P F Dullaart; Gerd Assmann; Ralph B D'Agostino; Gilles R Dagenais; Jackie A Cooper; Daan Kromhout; Altan Onat; Robert W Tipping; Agustín Gómez-de-la-Cámara; Annika Rosengren; Susan E Sutherland; John Gallacher; F Gerry R Fowkes; Edoardo Casiglia; Albert Hofman; Veikko Salomaa; Elizabeth Barrett-Connor; Robert Clarke; Eric Brunner; J Wouter Jukema; Leon A Simons; Manjinder Sandhu; Nicholas J Wareham; Kay-Tee Khaw; Jussi Kauhanen; Jukka T Salonen; William J Howard; Børge G Nordestgaard; Angela M Wood; Simon G Thompson; S Matthijs Boekholdt; Naveed Sattar; Chris Packard; Vilmundur Gudnason; John Danesh
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

10.  Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis.

Authors:  Kenneth Chan; Riyaz S Patel; Paul Newcombe; Christopher P Nelson; Atif Qasim; Stephen E Epstein; Susan Burnett; Viola L Vaccarino; A Maziar Zafari; Svati H Shah; Jeffrey L Anderson; John F Carlquist; Jaana Hartiala; Hooman Allayee; Kunihiko Hinohara; Bok-Soo Lee; Anna Erl; Katrina L Ellis; Anuj Goel; Arne S Schaefer; Nour Eddine El Mokhtari; Benjamin A Goldstein; Mark A Hlatky; Alan S Go; Gong-Qing Shen; Yan Gong; Carl Pepine; Ross C Laxton; John C Whittaker; W H Wilson Tang; Julie A Johnson; Qing K Wang; Themistocles L Assimes; Ute Nöthlings; Martin Farrall; Hugh Watkins; A Mark Richards; Vicky A Cameron; Axel Muendlein; Heinz Drexel; Werner Koch; Jeong Euy Park; Akinori Kimura; Wei-feng Shen; Iain A Simpson; Stanley L Hazen; Benjamin D Horne; Elizabeth R Hauser; Arshed A Quyyumi; Muredach P Reilly; Nilesh J Samani; Shu Ye
Journal:  J Am Coll Cardiol       Date:  2013-01-23       Impact factor: 24.094

View more
  23 in total

1.  Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.

Authors:  Ayman Jubran; Anna Zetser; Barak Zafrir
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

2.  [Correlation of lipoprotein(a) with clinical stability and severity of coronary artery lesions in patients with coronary artery disease].

Authors:  Yusheng Ma; Jiahuan Rao; Jieni Long; Lilong Lin; Jichen Liu; Zhigang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

Review 3.  Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.

Authors:  Xiaoming Jia; Jing Liu; Anurag Mehta; Christie M Ballantyne; Salim S Virani
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-30       Impact factor: 3.727

Review 4.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

5.  Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.

Authors:  Gregory G Schwartz; Christie M Ballantyne; Philip J Barter; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Stephen J Nicholls; Anders G Olsson; Prediman K Shah; Jean-Claude Tardif; John Kittelson
Journal:  JAMA Cardiol       Date:  2018-02-01       Impact factor: 14.676

6.  Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.

Authors:  Renata J M Engler; Emily Brede; Todd Villines; Marina N Vernalis
Journal:  Fed Pract       Date:  2019-11

7.  Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.

Authors:  Ulrich Laufs; Thimoteus Speer; Stephen Zewinger; Jochen Reiser; Vera Jankowski; Dalia Alansary; Eunsil Hahm; Sarah Triem; Mira Klug; Stefan J Schunk; David Schmit; Rafael Kramann; Christina Körbel; Emmanuel Ampofo; Matthias W Laschke; Simina-Ramona Selejan; Anna Paschen; Tobias Herter; Susanne Schuster; Günther Silbernagel; Martina Sester; Urban Sester; Gunter Aßmann; Robert Bals; Gerhard Kostner; Willi Jahnen-Dechent; Michael D Menger; Lucia Rohrer; Winfried März; Michael Böhm; Joachim Jankowski; Manfred Kopf; Eicke Latz; Barbara A Niemeyer; Danilo Fliser
Journal:  Nat Immunol       Date:  2019-12-09       Impact factor: 25.606

Review 8.  Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation.

Authors:  Ying X Gue; Diana A Gorog
Journal:  Int J Mol Sci       Date:  2017-08-25       Impact factor: 5.923

9.  Cohort profile: role of lipoproteins in cardiovascular disease-the LipidCardio study.

Authors:  Maximilian König; Samita Joshi; David M Leistner; Ulf Landmesser; David Sinning; Elisabeth Steinhagen-Thiessen; Ilja Demuth
Journal:  BMJ Open       Date:  2019-09-03       Impact factor: 2.692

10.  Contextualizing selection bias in Mendelian randomization: how bad is it likely to be?

Authors:  Apostolos Gkatzionis; Stephen Burgess
Journal:  Int J Epidemiol       Date:  2019-06-01       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.